Expression And Significance Of CD133 And Nanog In Epithelial Ovarian Carcinoma

Objective: Ovarian cancer is the most common cause of death from gynecologic malignancies and the second most common gynecologic cancer.Epithelial neoplasms are the most common malignant ovarian neoplasm,about 85%~90%.Most cases are diagnosed late,rates of survival have not changed appreciably over 30 years,resulting in poor clinical outcome.Therefore,research on effective,accurate diagnosis and treatment of ovarian cancer for improving patient quality of life,reducing mortality and recurrence,have great significance.It is well recognized that Nanog,a homeodomain-containing transcription factor and,is part of the key set of transcription factors that are involved in the maintenance of pluripotency and self-renewal in undifferentiated embryonic stem(ES)cells.Nanog is a product of a singlecopy gene on chromosome 12(12p13.31).Elevated Nanog was associated with high pathologic grade and poor prognosis in carcinoma patients.Recent work has implicated Nanog in various epithelial malignancies.Moreover,elevated Nanog was reported as a prognostic biomarker.CD133,is a product of a single-copy gene on chromosome 4(4p15.33)in human,and is a transmembrane glycoprotein of 865 amino acids with a total molecular weight of 120 kDa.Its human homolog was discovered in human hematopoietic stem cells.CD133 cell surface expression has been linked to stem cells,including endothelial progenitor cells,hematopoietic stem cells,fetal brain stem cells,embryonic epithelium,prostate epithelial stem cells,myogenic cells,and ependymal cells in the adult brain;as well as cancer stem cells.Studies have shown that abnormal expression of CD133 is associated with the malignant phenotype and invasion ability of tumor.Our experiment is aim to provide the reference for estimating the state of illness and of clinical treatment of epithelial ovarian carcinoma by detecting the expression levels and correlation of Nanog and CD133 in patients with ovarian epithelial carcinoma.Methods:1 Study groups:60 samples of ovarian epithelial carcinoma in patients undergone operation in our hospital from September 2012 to December 2013 were selected as experimental group(including 46 cases ovary serous adenocarcinoma,13 cases mucinous cystadenocarcinoma and one case ovarian endometrioid carcinoma),and 20 cases of normal ovarian tissue and 20 cases of benign epithelial ovarian tissue(including 13 cases ovaryserous cystadenoma and 7 cases mucinous cystadenoma)were selected as control.In accordance with the international union of obstetrics and gynecology surgicalpathologic staging(FIGO,2009),according to the organization will be statistical study of grading and lymph node metastasis.2 Sample collections: All ovarian tissues were obtained from postoperation.Ovarian tissues were immediately dissected and cutted into sizes of approximately lx1x1 cm.Immunohistochemical staining was carried out using the streptavidin perosidase method after the preparation that all ovarian tissues were fixed in 10% neutral buffered formalin and embedded in paraffin.3 Measurement indexes: The expresstion of Nanog and CD133 in the ovarian tissues were observed by Immunohistochemical techniques(streptavidin-perosidase,SP).4 Statistical analyses:SPSS version 19.0 was applied for all statistical analyses.Comparisons among groups were tested by X2 test.Linear correlation was assessed the linear relationship between two variables.For all tests performed,P<0.05 was considered statistically significant.Results:1 The positive expression rates of Nanog protein in normal ovarian,benign epithelial ovarian,ovarian cancer were 20%,35%,90%,respectively,the difference was statistically significant(P<0.05).The positive expression rates of Nanog protein increased gradually in patients with poorly differentiated,advanced FIGO stage.The positive expression rates of Nanog protein were not significant between high and low age group,neither between pelvic lymph node positive and negative.2 The positive expression rate of CD133 protein in normal ovarian,benign epithelial ovarian,ovarian cancer were 35%,50%,61.7%,respectively,the difference was statistically significant(P<0.05).In cancer group,the positive expression rates of Nanog protein increased gradually in patients with poorly differentiated,advanced FIGO stage.The positive expression rates of Nanog protein were not significant between high and low age group,neither between pelvic lymph node positive and negative.3 In cancer tissue,the relationship of Nanog and CD133 was positive correlated with Spearman correlation coefficient(r = 0.68,P<0.05).Conclusion:The higher positive rate and expressions of Nanog and CD133 in ovarian cancer than normal ovarian tissue,with tumor differentiation degree reducing,stage increase.Combined Nanog and CD133 in epithelial ovarian carcinoma may new opportunities for enhanced understanding of disease progression,metastasis and therapeutic response will emerge.